STRATA Skin Sciences Announces Completion of a Clinical Study

STRATA Skin Sciences recently announced the completion of a multi-center clinical study investigating the efficiency and efficacy of its FDA cleared Multi-Micro Dose (MMD) diagnostic tip accessory for the proprietary XTRAC 308 nm excimer laser.

Three separate clinics utilized the patent-pending MMD tip, in conjunction with the XTRAC laser, to filter the narrow band UVB light at delivery in order to calculate and customize the maximum non-blistering dose for each of the participating patients in the study.

The MMD tip simultaneously applies multiple level doses of energy to a specific area of a patient’s psoriatic plaque, thereby identifying the maximum sub-blistering energy dose for a particular treatment zone. Utilizing the results from these test patches, the physician can design the optimal therapeutic dose treatment for each patient. This proprietary process was trademarked by STRATA as the Optimal Therapeutic Dose (OTD) and is intended to provide faster patient outcomes and greater patient satisfaction. The clinical study was designed to measure increased efficacy and determine the minimum number of treatment sessions necessary to achieve desired clinical endpoints.

Following the OTD process, the physician determines the maximum non-blistering dose for the patient’s psoriatic plaque. Data have shown that higher doses of the XTRAC treatment achieved PASI-75 clearance in as little as two to four weekly treatments, as compared to an average of 6.2 treatments, shown in previously published studies at lower doses.

The statistical analysis of the clinical study results, based on the XTRAC treatment protocol which utilized the Optimal Therapeutic Dose (OTD), revealed the following findings:

-92% of the included participants responded to treatment by achieving a reduction in mPASI score of 75% or more.

-As compared to the current average of 16-20 treatments conducted with NB-UVB 308nm devices, the treatment produced statistically significant mPASI improvement by the second treatment. It took an average of four sessions for patients to reduce mPASI by 50% or more relative to baseline.

-Patients were followed post treatment and have maintained reduction in mPASI score of 50% or more for 60 days.

-Further, statistical survival models predict mPASI scores to stay below 50% of baseline for 78 days.

The company anticipates the full clinical study report to be submitted for publication.

Dr. Ben Lockshin, former Chair of the Research Committee and on the Board of Directors for the National Psoriasis Foundation (NPF) and a principal investigator on this study, said “I am pleased to see how quickly my patients can achieve meaningful improvement in just a few treatments. I believe this will greatly increase patient satisfaction.”

Dr. Lockshin, has engaged with the company to become the first commercial site providing OTD XTRAC treatments using the MMD tip, and further commented, “I believe integrating the OTD approach will allow me to provide the safe and effective treatment that reduces the time commitment and cost for my patients while achieving the clinical results we have come to expect with XTRAC.”

Dr. Dolev Rafaeli, STRATA’s Chief Executive Officer, noted “Introducing the Optimal Therapeutic Dose treatment protocol and making it commercially available is a very important milestone for STRATA and its partner clinics. This new protocol will provide faster patient outcomes, greater patient satisfaction, lower costs for payers and patients alike, and increased patient traffic to our partner clinics. This dynamic combination of MMD’s proprietary technology and the OTD protocol is exclusively available to our physician partners, differentiating their clinical delivery and adding to the technological superiority of the XTRAC platform as compared with all other available treatment modalities. We look forward to the expansion of the commercial use of the MMD diagnostic tip across our partner network of over 1,000 providers.”

 STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN MicroSystem, marketed specifically for the intended use of micropigmentation. Nothing in this press release is intended to indicate that the FDA has cleared the MMD device for marketing or that the sought after indications for use will be allowed by the FDA.

The Company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 740 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners. For more information, visit www.strataskinsciences.com.